Article

Informing participants of allocation to placebo at trial closure: postal survey.

Department of Health Sciences, University of York, York YO10 5DD.
BMJ (Clinical research ed.) 01/2003; 325(7376):1329. DOI:Impact Factor: 14.093 pp.1329
Source: PubMed

ABSTRACT To assess whether and how investigators of placebo controlled randomised trials inform participants of their treatment allocation at trial closure and to assess barriers to feedback.
Postal survey with a semistructured questionnaire.
All investigators who published a placebo controlled randomised trial in 2000 in five leading medical journals, and a random sample of 120 trials listed in the national research register database.
Number of investigators who informed participants of their treatment allocation at trial closure, methods for delivering the information, and barriers to unmasking treatment.
45% of investigators informed either all or most participants of their treatment allocation, and 55% did not inform any participant or only informed those who asked. The main reasons for not informing participants were that the investigators never considered this option (40%) or to avoid biasing results at study follow up (24%).
Further research is required to examine sensitive ways to communicate treatment information to trial participants.

0 0
 · 
0 Bookmarks
 · 
31 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

main reasons
 
national research
 
Postal survey
 
random sample
 
randomised trial
 
randomised trials
 
sensitive ways
 
treatment information
 
trial closure
 
unmasking treatment